Nanoformulations, like liposomes, lipid nanoparticles, micelles and metal organic frameworks, are versatile systems for drug delivery. Multiple drug delivery routes have been investigated for nanoformulations, and the commercialized nanoformulations (Doxil®, Abraxane®, Onivyde®, etc.) mainly adopts intravenous injection as the administration approach. It should be noted that intravenous injection often leads to pain, inflammation and trauma of the injection site, and even causes systematic infections in some cases. As a result, intravenous injection is generally associated with poor patient compliance, which is detrimental for the safety of disease therapy. Besides, in some pathological scenarios, the lesion sites are located in certain organs, and the corresponding delivery methods can be employed to improve the treatment efficacy. For example, pulmonary delivery can be an optimal approach for lung infection treatment. From this perspective, if alternative drug delivery approaches other than intravenous injection can be developed for nanoformulations, the efficacy and safety of therapeutics may be further enhanced. We indeed witness an increase in the interests of nanoformulations for non-intravenous drug delivery (e.g., pulmonary, intranasal, dermal and rectal) in the scientific community, and many of the relevant publications have made great contributions to the understanding of innovative nanomedicine design. Article, (mini) review, perspective and other types of content permitted by the guide for authors are all welcome. Please notice that the paper should directly related with non-intravenous drug delivery routes. We are looking forward to receiving your interesting papers.